Evidence map›Paper›PMID 32837030›Full record

ReviewIndian journal of clinical biochemistry : IJCB2020

Novel Stem Cells and Nucleic Acid-Based Vaccine Trials Against Viral Outbreak: A Systematic Evaluation During COVID-2019 Pandemic.

Chandan Kumar Maurya, Radhieka Misra, Praveen Sharma, Neha Singh, Harshita Awasthi, Ruchika Agrawal, Sanjeev Misra, Shailendra Dwivedi

Open access · bronzeAbstract readReview
In one paragraph

Review in Indian journal of clinical biochemistry : IJCB, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Chandan Kumar MauryaDepartment of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, 273008 India.
Radhieka MisraEra's Lucknow Medical College, and Hospital, Lucknow, 226003 India.
Praveen SharmaDepartment of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 342005 India.
Neha SinghDepartment of Biotechnology, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, 211007 India.
Harshita AwasthiDepartment of Biochemistry, Lucknow University Lucknow, Lucknow, 226007 India.
Ruchika AgrawalDepartment of Ear Nose and Throat, All India Institute of Medical Sciences, Gorakhpur, 273008 India.
Sanjeev MisraDepartment of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, 342005 India.
Shailendra DwivediDepartment of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, 273008 India.ORCID 0000-0003-2781-1009
All India Institute of Medical Sciences Jodhpur · INBaba Raghav Das Medical College · INAll India Institute of Medical Sciences · INEra's Lucknow Medical College and Hospital · INSam Higginbottom Institute of Agriculture · INUniversity of Lucknow · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreak, the cause of coronavirus disease (COVID-19), has influenced health globally. So far, there are no established management options and prophylaxis for those who have been exposed to SARS-CoV-2, and those who develop COVID-19. Documented scientific evidences in similar viral outbreaks in past suggested few therapy regimens. These rather have not shown promising results in management of current pandemic. So, in the current review, we are exploring novel treatment strategies and therapies that are being explored and are in clinical and preclinical stages of research. To explore more about the same, we directed our search towards stem cell based, DNA based, or RNA based vaccines against COVID-19 under development by various universities, institutes or pharmaceutical companies. The current scientific literature and database search were performed by exploring various Trials registry (NIH: https://clinicaltrials.gov/ and https://www.coronavirus.gov) and Chinese clinical trial registry http://www.chictr.org.cn/) and for preclinical trials various University, Institutions, Pharmaceutical companies websites and news bulletins along with google search were checked routinely from 3rd March 2020 to 16 May 2020. The term "Stem Cell therapy and COVID-19", "Mesenchymal stem cell and corona 2019 virus", "DNA Vaccines and COVID-19, RNA Vaccines and COVID-19" and "Cell-based therapy with SARS-CoV-2, University/Institutions and COVID-19 research" were used. The vaccine trials (Stem Cells/DNA/RNA) which were cancelled were not included in this review. Similarly, few others like repurposing of drugs, Nano Vaccines, other miscellaneous trials of Herbs, Music therapy etc., were also excluded. In the present review, we have included the various novel therapies like stem cell therapy, DNA or RNA vaccines which are under development and if proven successful may have a lasting impact on the health industry.

Indexed as

COVID-19DNA vaccineNucleic acid based vaccinesRNA vaccineStem cell based vaccineViral disease

Identifiers

PMID32837030
PMCPMC7347658
OpenAlexW3041725709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.